barasertib-hQPA   

GtoPdb Ligand ID: 5663

Synonyms: AZD-1152HQPA | AZD2811 [1,3] | INH 34
Compound class: Synthetic organic
Comment: This is the active form of the phosphate pro-drug barasertib. It is an inhibitor of Aurora kinase B [4].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 14
Topological polar surface area 128.29
Molecular weight 507.24
XLogP 3.02
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Canonical SMILES OCCN(CCCOc1ccc2c(c1)ncnc2Nc1[nH]nc(c1)CC(=O)Nc1cccc(c1)F)CC
Isomeric SMILES OCCN(CCCOc1ccc2c(c1)ncnc2Nc1[nH]nc(c1)CC(=O)Nc1cccc(c1)F)CC
InChI InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)
InChI Key QYZOGCMHVIGURT-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
This drug is in Phase I clinical trial in patients with advanced solid tumors [6], although its use is limited by the need for continuous i.v. infusion. To overcome this limitation, a nanoparticle formulation of AZD1152-hQPA known as AZD2811 has been developed [3] and is being evaluated in early stage clinical trials for AML and some advanced solid tumours (see NCT03217838, NCT03366675 and NCT02579226 [1] for example) .
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02579226 A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Phase 1 Interventional AstraZeneca
NCT03217838 Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Patients. Phase 1/Phase 2 Interventional AstraZeneca
NCT03366675 AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] Phase 2 Interventional Samsung Medical Center